Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,047 DKK | -4.80% | -3.57% | -21.28% |
Mar. 27 | Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 04 | FDA Extends Review of Zevra's Arimoclomol by Three Months | DJ |
Sales 2022 | - | Sales 2023 | - | Capitalization | 46.96M 329M |
---|---|---|---|---|---|
Net income 2022 | 26M 182M | Net income 2023 | -26M -182M | EV / Sales 2022 | - |
Net cash position 2022 | 42.46M 298M | Net cash position 2023 | 18.21M 128M | EV / Sales 2023 | - |
P/E ratio 2022 |
1.19
x | P/E ratio 2023 |
-1.8
x | Employees | 1 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 59.56% |
1 day | -4.53% | ||
1 week | -4.55% | ||
Current month | -12.49% | ||
1 month | -9.72% | ||
3 months | -19.23% | ||
6 months | +14.13% | ||
Current year | -21.05% |
Managers | Title | Age | Since |
---|---|---|---|
Jakob Bendtsen
CEO | Chief Executive Officer | 46 | 23-05-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jakob Have
BRD | Director/Board Member | 43 | 23-05-16 |
Chairman | 53 | 23-05-16 | |
Jakob Bendtsen
CEO | Chief Executive Officer | 46 | 23-05-16 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 1,047 | -4.80% | 66 |
24-04-18 | 1,100 | +4.74% | 7 |
24-04-17 | 1,050 | +0.04% | 3 |
24-04-16 | 1,050 | -0.02% | 2 |
24-04-15 | 1,050 | -4.56% | 13 |
Delayed Quote Nasdaq Copenhagen, April 19, 2024 at 06:44 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-21.05% | 5.55M | |
-3.30% | 102B | |
+1.79% | 96.07B | |
-1.14% | 21.66B | |
-18.35% | 20.77B | |
-7.96% | 18.53B | |
-40.31% | 16.91B | |
-26.84% | 13.79B | |
+0.59% | 13.33B | |
+20.86% | 10.94B |
- Stock Market
- Equities
- ORPHA Stock